Neurogene (NGNE) Earnings Date & Reports

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning)... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

NGNE is expected to report earnings to fall 97.22% to -2 cents per share on November 14

Q3'23

Est.

$-0.03

Q1'25

Missed

by $0.01

Q2'23

Est.

$-0.04

Q1'23

Missed

by $0.04

Q4'22

Missed

by $0.05

The last earnings report on May 09 showed earnings per share of -108 cents, missing the estimate of -107 cents. With 58.19K shares outstanding, the current market capitalization sits at 240.74M.

View a ticker or compare two or three

Compare

NGNE